Loading clinical trials...
Loading clinical trials...
A Randomized, Phase 3, Open-label Study to Investigate Pharmacokinetics, Safety, and Efficacy of Subcutaneous Compared to Intravenous Frexalimab in Adult Participants With Multiple Sclerosis
Conditions
Interventions
Frexalimab
Frexalimab
+1 more
Locations
18
United States
North Central Neurology Associates- Site Number : 8401100
Cullman, Alabama, United States
Alabama Neurology Associates- Site Number : 8400115
Homewood, Alabama, United States
Perseverance Research Center- Site Number : 8400138
Scottsdale, Arizona, United States
Private Practice - Dr. Regina Berkovich- Site Number : 8400005
West Hollywood, California, United States
Neurology of Central Florida- Site Number : 8400147
Altamonte Springs, Florida, United States
Aqualane Clinical Research- Site Number : 8400026
Naples, Florida, United States
Start Date
January 14, 2026
Primary Completion Date
July 15, 2027
Completion Date
November 30, 2028
Last Updated
April 21, 2026
NCT05748015
NCT04876339
NCT05344469
NCT06276634
NCT07225504
NCT06599307
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610Contact-US@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions